Toad-skin insulin booster (Insulin-releasing peptide 21)

What this is

Insulin-releasing peptide 21 is a small peptide found in the skin secretions of Bombina variegata, the yellow-bellied toad native to central Europe. It belongs to the bombesin family — a group of signaling molecules first discovered in amphibian skin in the early 1970s that have close structural counterparts in mammalian tissue. The peptide was one of several insulin-releasing compounds isolated from B. variegata skin by Marenah and colleagues (Biological Chemistry, 2004); when tested against glucose-responsive pancreatic beta cells in culture, it produced a 1.5–3.5-fold increase in insulin release compared to glucose alone, without measurable toxicity to the cells. The stored sequence QRLGHQWAVGHLM represents the 13-residue backbone; the native isolated peptide additionally carries a pyroglutamate (pGlu) cap at the N-terminus — written Pyr-QRLGHQWAVGHLM — that is not encoded in the stored one-letter sequence.

History

Bombesin was first isolated from the skin of Bombina bombina (the fire-bellied toad) in the early 1970s by Vittorio Erspamer's group in Italy. Amphibian skin proved to be a remarkably productive source of biologically active peptides — the skins of various frog and toad species secrete complex mixtures used for defense, antimicrobial protection, and signaling. Insulin-releasing peptide 21 was characterized as part of a systematic survey of Bombina variegata secretions by Marenah and colleagues (2004), who used mild electrical stimulation of the dorsal skin to collect secretions, purified them by reverse-phase HPLC into 44 fractions, and screened each fraction for insulin-releasing activity in BRIN-BD11 cells (a glucose-responsive clonal beta-cell line). Of the active fractions, peak 21 (mass 1641.7 Da) was sequenced by Edman degradation and mass spectrometry, revealing the structure Pyr-QRLGHQWAVGHLM — an analog of bombesin in which histidine occupies position 6 rather than the asparagine found in native bombesin (Pyr-QRLGNQWAVGHLM from Bombina bombina). The authors described it as "His6 bombesin" (Marenah and colleagues, 2004).

What it does

In pancreatic beta cells, this peptide stimulates the release of insulin. In the study by Marenah and colleagues (2004), incubation of BRIN-BD11 cells with the purified peptide at a background glucose concentration of 5.6 mM produced a 1.5–3.5-fold increase in insulin secretion relative to glucose alone; no cytotoxic effects were observed at the concentrations tested. This activity places it in the insulinotropic class of amphibian skin peptides alongside other bombesin-related compounds. Bombesin-family peptides as a class are known to act through G protein-coupled receptors — the gastrin-releasing peptide receptor (GRPR/BB2) being the primary form in the pancreas — triggering a signaling cascade through phospholipase C that generates inositol trisphosphate and diacylglycerol, raising intracellular calcium and driving insulin secretion in a biphasic pattern. Whether the His6 substitution meaningfully changes receptor affinity or potency relative to native bombesin has not been reported in the dossier for this card.

Evidence

• Human: No human data. This peptide has been characterized only in isolated cell assays and has not been studied in animals or humans in this form.
• Animal: Not reported.
• In vitro: 1.5–3.5-fold increase in insulin release over 5.6 mM glucose baseline in glucose-responsive BRIN-BD11 clonal beta cells; no cytotoxic effects observed (Marenah and colleagues, 2004).

Known effects

• Insulin secretion stimulation — In vitro, BRIN-BD11 cells (Marenah and colleagues, 2004)

Open questions

• Whether the His6 substitution alters binding affinity or potency at bombesin receptors (GRPR/BB2, NMBR/BB1) compared to native bombesin has not been characterized.
• The contribution of the pyroglutamate N-cap to insulinotropic activity is not established for this variant.
• No in vivo metabolic or pharmacokinetic data exist for this peptide.
• Potential mammalian counterparts or endogenous analogs with similar sequence have not been described.

Related peptides

• Gastrin-releasing peptide (GRP) — the primary mammalian counterpart of bombesin; shares the C-terminal active-core sequence and acts at GRPR to stimulate gastric acid secretion, pancreatic release, and appetite signaling.
• Rohdei-litorin — another amphibian skin bombesin-family peptide, functionally analogous to neuromedin B, isolated from Phyllomedusa rohdei.
• Caerulein — a cholecystokinin-family peptide from Australian tree frog skin; similarly discovered via amphibian skin bioassay, with overlapping pancreatic secretory effects through a distinct receptor.